A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma

Trial Profile

A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs ATU 027 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Silence Therapeutics
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by EudraCT record.
    • 23 Nov 2015 Planned End Date changed from 15 Aug 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 17 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top